Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain

International Journal of Neuropsychopharmacology

Volumn 11, Issue 6, 2008, Pages 743-763

  Riegert, Céline ^a,b   Wedekind, Franziska ^a   Hamida, Sami Ben ^b   Rutz, Susanne ^a   Rothmaier, Anna Katharina ^a   Jones, Byron C ^c   Cassel, Jean Christophe ^b   Jackisch, Rolf ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Université de Strasbourg Faculté de Psychologie   (France)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

EtOH; Hippocampus; MDMA; Neocortex; Neurotransmitter release; Striatum

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCHOLINE; ALCOHOL; DOPAMINE; DOPAMINE RECEPTOR; FLUVOXAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NICOTINIC RECEPTOR; NOMIFENSINE; SEROTONIN; SEROTONIN 2 RECEPTOR;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HIPPOCAMPUS; LOCOMOTION; MALE; NEOCORTEX; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTRIC STIMULATION; ETHANOL; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, LONG-EVANS; SEROTONIN; SEROTONIN AGENTS; TRITIUM;

EID: 50849128531     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008481     Document Type: Article

References (108)

1. Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A, Di Chiara G (2001). Intravenous administration of ecstasy (3,4- methylendioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. European Journal of Pharmacology 418, 207-211.
2. Agid Y, Guyenet P, Glowinski J, Beaujouan JC, Javoy F (1975). Inhibitory influence of the nigrostriatal dopamine system on the striatal cholinergic neurons in the rat. Brain Research 86, 488-492.
3. Alcantara AA, Chen V, Herring BE, Mendenhall JM, Berlanga ML (2003). Localization of dopamine D2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat. Brain Research 986, 22-29.
4. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology & Therapeutics 113, 296-320.
5. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA (2005). Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55, 242-251.
6. Barrett SP, Darredeau C, Pihl RO (2006). Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology 21, 255-263.
7. Baumann MH, Wang X, Rothman RB (2007). 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats : a reappraisal of past and present findings. Psychopharmacology (Berlin) 189, 407-424.
8. Berger UV, Gu XF, Azmitia EC (1992). The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. European Journal of Pharmacology 215, 153-160.
9. Bertorelli R, Consolo S (1990). D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. Journal of Neurochemistry 54, 2145-2148.
10. Birthelmer A, Lazaris A, Schweizer T, Jackisch R, Cassel JC (2003a). Presynaptic regulation of neurotransmitter release in the cortex of aged rats with differential memory impairments. Pharmacology Biochemistry and Behaviour 75, 147-162.
11. Birthelmer A, Stemmelin J, Jackisch R, Cassel JC (2003b). Presynaptic modulation of acetylcholine, noradrenaline, and serotonin release in the hippocampus of aged rats with various levels of memory impairments. Brain Research Bulletin 60, 283-296.
12. Borghese CM, Henderson LA, Bleck V, Trudell JR, Harris RA (2003). Sites of excitatory and inhibitory actions of alcohols on neuronal alpha2beta4 nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics 307, 42-52.
13. Brodie MS, Shefner SA, Dunwiddie TV (1990). Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Research 508, 65-69.
14. Brodie MS, Trifunovic RD, Shefner SA (1995). Serotonin potentiates ethanol-induced excitation of ventral tegmental area neurons in brain slices from three different rat strains. Journal of Pharmacology and Experimental Therapeutics 273, 1139-1146.
15. Bunney EB, Appel SB, Brodie MS (2000). Cocaine potentiates ethanol-induced excitation of dopaminergic reward neurons in the ventral tegmental area. Journal of Pharmacology and Experimental Therapeutics 293, 383-389.
16. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO (1999). Olanzapine: a basic science update. British Journal of Psychiatry (Suppl.) 37, 36-40.
17. Callaway CW, Wing LL, Geyer MA (1990). Serotonin release contributes to the locomotor stimulant effects of 3,4- methylenedioxymethamphetamine in rats. Journal of Pharmacology and Experimental Therapeutics 254, 456-464.
18. Cami J, Farre M, Gonzalez ML, Segura J, de la Torre R (1998). Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Developments in Alcoholism 14, 437-455.
19. 3H]dopamine release from hippocampus. Journal of Pharmacology and Experimental Therapeutics 312, 1298-1304.
20. Cassel JC, Jeltsch H, Koenig J, Jones BC (2004). Locomotor and pyretic effects of MDMA-ethanol associations in rats. Alcohol 34, 285-289.
21. Cassel JC, Riegert C, Rutz S, Koenig J, Rothmaier K, Cosquer B, Lazarus C, Birthelmer A, Jeltsch H, Jones BC, Jackisch R (2005). Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat. Neuropsychopharmacology 30, 1870-1882.
22. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. British Journal of Pharmacology 121, 1735-1743.
23. Darstein M, Albrecht C, Lopez-Francos L, Knorle R, Holter SM, Spanagel R, Feuerstein TJ (1998). Release and accumulation of neurotransmitters in the rat brain : acute effects of ethanol in vitro and effects of long-term voluntary ethanol intake. Alcoholism : Clinical and Experimental Research 22, 704-709.
24. Davies J, Watkins JC (1982). Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Research 235, 378-386.
25. Daws LC, Montanez S, Munn JL, Owens WA, Baganz NL, Boyce-Rustay JM, Millstein RA, Wiedholz LM, Murphy DL, Holmes A (2006). Ethanol inhibits clearance of brain serotonin by a serotonin transporter-independent mechanism. Journal of Neuroscience 26, 6431-6438.
26. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. British Journal of Clinical Pharmacology 49, 104-109.
27. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences USA 85, 5274-5278.
28. 2+. Journal of Neurochemistry 52, 1680-1685.
29. Ehret A, Haaf A, Jeltsch H, Heimrich B, Feuerstein TJ, Jackisch R (2001). Modulation of electrically evoked acetylcholine release in cultured rat septal neurones. Journal of Neurochemistry 76, 555-564.
30. Ennis C, Kemp JD, Cox B (1981). Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. Journal of Neurochemistry 36, 1515-1520.
31. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI (2001). 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berlin) 154, 251-260.
32. Farre M, de la Torre R, Gonzalez ML, Teran MT, Roset PN, Menoyo E, Cami J (1997). Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. Journal of Pharmacology and Experimental Therapeutics 283, 164-176.
33. Fink KB, Göthert M (2007). 5-HT receptor regulation of neurotransmitter release. Pharmacological Reviews 59, 360-417.
34. Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A (2000). MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. European Journal of Neuroscience 12, 1385-1390.
35. Foltin RW, Fischman MW, Levin FR (1995). Cardiovascular effects of cocaine in humans: laboratory studies. Drug and Alcohol Dependence 37, 193-210.
36. Fozard JR, Gittos MW (1983). Selective blockade of 5-hydroxytryptamine neuronal receptors by benzoic esters of tropine. British Journal of Pharmacology 110, 511P.
37. Gartside SE, McQuade R, Sharp T (1997). Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release : comparison between dorsal and median raphe 5-HT systems. Neuropharmacology 36, 1697-1703.
38. Goni-Allo B, Ramos M, Herv'as I, Lasheras B, Aguirre N (2006). Studies on striatal neurotoxicity caused by the 3,4- methylenedioxymethamphetamine/malonate combination: implications for serotonin/dopamine interactions. Journal of Psychopharmacology 20, 245-256.
39. 3H]dopamine release from synaptosomes prepared from mouse striatum. Journal of Neurochemistry 59, 848-856.
40. 3H]dopamine release from synaptosomes prepared from mouse striatum. Journal of Neurochemistry 59, 848-856.
41. 3H]dopamine release from mouse striatal synaptosomes. Journal of Neurochemistry 62, 1390-1398.
42. 3H]dopamine release from synaptosomes prepared from four mouse brain regions. Journal of Pharmacology and Experimental Therapeutics 301, 651-660.
43. Green AR, Cross AJ, Goodwin GM (1995). Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology (Berlin) 119, 247-260.
44. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacological Reviews 55, 463-508.
45. Greenamyre JT, Young AB (1989). Synaptic localization of striatal NMDA, quisqualate and kainate receptors. Neuroscience Letters 101, 133-137.
46. Gudelsky GA, Nash JF (1996). Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine : implications for serotonin-dopamine interactions. Journal of Neurochemistry 66, 243-249.
47. Hamida SB, Bach S, Plute E, Jones BC, Kelche C, Cassel JC (2006). Ethanol-ecstasy (MDMA) interactions in rats : preserved attenuation of hyperthermia and potentiation of hyperactivity by ethanol despite prior ethanol treatment. Pharmacology Biochemistry and Behaviour 84, 162-168.
48. Hamida SB, Plute E, Bach S, Lazarus C, Tracqui P, Kelche C, de Vasconcelos AP, Jones BC, Cassel JC (2007). Ethanol-MDMA interactions in rats : the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination. Psychopharmacology (Berlin) 192, 555-569.
49. Harris RA (1999). Ethanol actions on multiple ion channels: which are important? Alcoholism : Clinical and Experimental Research 23, 1563-1570.
50. Henn C, Löffelholz K, Klein J (1998). Stimulatory and inhibitory effects of ethanol on hippocampal acetylcholine release. Naunyn Schmiedeberg's Archives of Pharmacology 357, 640-647.
51. Herman JP, Lupp A, Abrous N, Le Moal M, Hertting G, Jackisch R (1988). Intrastriatal dopaminergic grafts restore inhibitory control over striatal cholinergic neurons. Experimental Brain Research 73, 236-248.
52. Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002). 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 300, 236-244.
53. Hertting G, Zumstein A, Jackisch R, Hoffmann I, Starke K (1980). Modulation by endogenous dopamine of the release of acetylcholine in the caudate nucleus of the rabbit. Naunyn Schmiedeberg's Archives of Pharmacology 315, 111-117.
54. Holm KJ, Spencer CM (1999). Entacapone. A review of its use in Parkinson's disease. Drugs 58, 159-177.
55. Ikarashi Y, Takahashi A, Ishimaru H, Arai T, Maruyama Y (1997). Suppression of cholinergic activity via the dopamine D2 receptor in the rat striatum. Neurochemistry International 30, 191-197.
56. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31, 424-430.
57. Jackisch R, Zumstein A, Hertting G, Starke K (1980). Interneurones are probably not involved in the presynaptic dopaminergic control of dopamine release in rabbit caudate nucleus. Naunyn-Schmiedeberg's Archives of Pharmacology 314, 129-133.
58. Jamal M, Ameno K, Ameno S, Morishita J, Wang W, Kumihashi M, Ikuo U, Miki T, Ijiri I (2007). Changes in cholinergic function in the frontal cortex and hippocampus of rat exposed to ethanol and acetaldehyde. Neuroscience 144, 232-238.
59. Jamal M, Ameno K, Wang W, Kumihashi M, Ameno S, Ikuo U, Shinji A, Ijiri I (2005). Inhibition of acetaldehyde metabolism decreases acetylcholine release in medial frontal cortex of freely moving rats. Brain Research 1039, 90-96.
60. Johnson EA, O'Callaghan JP, Miller DB (2004). Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berlin) 173, 278-286.
61. 3H]dopamine release in rat striatal slices via glutamate release. Molecular Pharmacology 58, 312-318.
62. Knoll J (1987). R-(-)deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. Journal of Neural Transmission (Suppl.) 25, 45-66.
63. Koch S, Galloway MP (1997). MDMA induced dopamine release in vivo: role of endogenous serotonin. Journal of Neural Transmission 104, 135-146.
64. 3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse. Brain Research. Developmental Brain Research 78, 142-146.
65. Lapper SR, Bolam JP (1992). Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51, 533-545.
66. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985). Receptor-binding properties in vitro and in vivo of ritanserin : a very potent and long acting serotonin-S2 antagonist. Molecular Pharmacology 27, 600-611.
67. Löf E, Ericson M, Stomberg R, Soderpalm B (2007). Characterization of ethanol-induced dopamine elevation in the rat nucleus accumbens. European Journal of Pharmacology 555, 148-155.
68. Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR, Ensenat P, Muela F (2004). The designer drug situation in Ibiza. Forensic Science International 140, 195-206.
69. Lupp A, Lücking CH, Koch R, Jackisch R, Feuerstein TJ (1992). Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. Journal of Pharmacology and Experimental Therapeutics 263, 717-724.
70. MacLeod AM, Merchant KJ, Brookfield F, Kelleher F, Stevenson G, Owens AP, Swain CJ, Casiceri MA, Sadowski S, Ber E, et al. (1994). Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. Journal of Medicinal Chemistry 37, 1269-1274.
71. Martin-Iverson MT, Burger LY (1995). Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Molecular Neurobiology 11, 31-46.
72. Mascia MP, Maiya R, Borghese CM, Lobo IA, Hara K, Yamakura T, Gong DH, Beckstead MJ (2001). Does acetaldehyde mediate ethanol action in the central nervous system? Alcoholism : Clinical and Experimental Research 25, 1570-1575.
73. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. British Journal of Pharmacology 135, 170-180.
74. Mehler-Wex C, Riederer P, Gerlach M (2006). Dopaminergic dysbalance in distinct basal ganglia neurocircuits : implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Research 10, 167-179.
75. Mlinar B, Corradetti R (2003). Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. European Journal of Neuroscience 18, 1559-1571.
76. Oesterheld JR, Armstrong SC, Cozza KL (2004). Ecstasy : pharmacodynamic and pharmacokinetic interactions. Psychosomatics 45, 84-87.
77. Pan WJ, Hedaya MA (1999). Cocaine and alcohol interactions in the rat : contribution of cocaine metabolites to the pharmacological effects. Journal of Pharmacological Sciences 88, 468-476.
78. Panagis G, Hildebrand BE, Svensson TH, Nomikos GG (2000). Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 35, 15-25.
79. Pedersen W, Skrondal A (1999). Ecstasy and new patterns of drug use : a normal population study. Addiction 94, 1695-1706.
80. Phelps PE, Houser CR, Vaughn JE (1985). Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. Journal of Comparative Neurology 238, 286-307.
81. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, Grady SR (2003). Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Molecular Pharmacology 63, 1169-1179.
82. Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX (1990). The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. Journal of Pharmacology and Experimental Therapeutics 254, 71-82.
83. Rudnick G, Wall SC (1992). The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences USA 89, 1817-1821.
84. Sabol KE, Seiden LS (1998). Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Research 806, 69-78.
85. 3H] metabolites in rat striatum by nicotinic drugs. Brain Research 242, 99-106.
86. Sarhan H, Fillion G (1999). Differential sensitivity of 5-HT1B auto and heteroreceptors. Naunyn Schmiedeberg's Archives of Pharmacology 360, 382-390.
87. 3H]dopamine from rat striatal synaptosomes : further evidence using 5-HT moduline, polyclonal 5-HT1B receptor antibodies and 5-HT1B receptor knock-out mice. Naunyn Schmiedeberg's Archives of Pharmacology 361, 12-18.
88. Schifano F (2004). A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berlin) 173, 242-248.
89. Soderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA (2000). Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behavioural Brain Research 113, 85-96.
90. Starke K, Hedler L, Steppeler A (1981). Metabolism of endogenous and exogenous noradrenaline in guinea-pig atria. Naunyn Schmiedeberg's Archives of Pharmacology 317, 193-198.
91. 3H-monoamines in brain slices. Biochemical Pharmacology 31, 2395-2402.
92. Stoof JC, De Boer T, Sminia P, Mulder AH (1982). Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. European Journal of Pharmacology 84, 211-214.
93. Stoof JC, Drukarch B, de Boer P, Westerink BH, Groenewegen HJ (1992). Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 47, 755-770.
94. Tabakoff B, Hoffman PL (1996). Alcohol addiction: an enigma among us. Neuron 16, 909-912.
95. Thielen RJ, Bare DJ, McBride WJ, Lumeng L, Li TK (2002). Ethanol-stimulated serotonin release in the ventral hippocampus: an absence of rapid tolerance for the alcohol-preferring P rat and insensitivity in the alcohol-nonpreferring NP rat. Pharmacology Biochemistry and Behavior 71, 111-117.
96. Thielen RJ, Morzorati SL, McBride WJ (2001). Effects of ethanol on the dorsal raphe nucleus and its projections to the caudate putamen. Alcohol 23, 131-139.
97. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence 55, 105-115.
98. Wichems CH, Hollingsworth CK, Bennett BA (1995). Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release. Brain Research 695, 10-18.
99. Winer BJ (1971). Statistical Principles in Experimental Design. New York, London: McGraw-Hill.
100. Wonnacott S (1997). Presynaptic nicotinic ACh receptors. Trends in Neurosciences 20, 92-98.
101. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000). Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. European Journal of Pharmacology 393, 51-58.
102. Wozniak KM, Pert A, Mele A, Linnoila M (1991). Focal application of alcohols elevates extracellular dopamine in rat brain : a microdialysis study. Brain Research 540, 31-40.
103. Yamamoto BK, Nash JF, Gudelsky GA (1995). Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. Journal of Pharmacology and Experimental Therapeutics 273, 1063-1070.
104. Yan QS (1999). Extracellular dopamine and serotonin after ethanol monitored with 5-minute microdialysis. Alcohol 19, 1-7.
105. Yan QS, Reith ME, Jobe PC, Dailey JW (1996). Focal ethanol elevates extracellular dopamine and serotonin concentrations in the rat ventral tegmental area. European Journal of Pharmacology 301, 49-57.
106. Yim HJ, Schallert T, Randall PK, Gonzales RA (1998). Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. Alcoholism : Clinical and Experimental Research 22, 367-374.
107. Yoshimoto K, McBride WJ, Lumeng L, Li TK (1992). Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 9, 17-22.
108. Zumstein A, Karduck W, Starke K (1981). Pathways of dopamine metabolism in the rabbit caudate nucleus in vitro. Naunyn Schmiedeberg's Archives of Pharmacology 316, 205-217.